联合阳极HD-tDCS与虚拟现实疗法恢复慢性卒中患者上肢功能(ReArm):随机对照试验研究方案
主要结局为Wolf运动功能测试,假设真刺激组上肢功能改善更大且更持久。
要点
- 慢性卒中患者在3周VRT和常规治疗中加用阳极HD-tDCS可能改善上肢功能。
- 主要结局为Wolf运动功能测试,评估时间点为基线、康复结束时和3个月后。
- 采用四盲、随机、假对照设计,真刺激参数为2 mA、20 min,假刺激为2 mA、30 s。
核心结论
- 这是首个评估在慢性卒中患者上肢VRT和常规治疗期间加用HD-tDCS影响的试验。
- 假设真刺激组上肢功能改善将大于且比假刺激组更持久。
研究设计与样本
- 四盲、随机、假对照、双中心、两臂平行干预研究。
- 患者接受标准3周住院康复方案,包括13天VRT(Armeo Spring,1次/天,30 min/次)和常规治疗(3次/天,30 min/次)。
- 29例接受真刺激(4x1阳极HD-tDCS montage,2 mA,20 min)作用于同侧初级运动皮层,另29例接受主动假刺激(2 mA,30 s)。
- 结局在基线、康复结束时和3个月后评估。
关键数值与推荐
- 主要结局为Wolf运动功能测试。
- 次要结局包括上肢功能(Box and Block Test)、损伤(Fugl Meyer Upper Extremity)、代偿(Proximal Arm Non-Use)、ADL(Actimetry、Barthel Index)。
- 其他/探索性结局包括疼痛、疲劳、努力和表现、运动学以及功能运动任务中运动皮层区域激活。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After a stroke, 80% of the chronic patients have difficulties to use their paretic upper limb (UL) in activities of daily life (ADL) even after rehabilitation. Virtual reality therapy (VRT) and anodal transcranial direct current stimulation (tDCS) are two innovative methods that have shown independently to positively impact functional recovery of the paretic UL when combined with conventional therapy. The objective of the project will be to evaluate the impact of adding anodal high-definition (HD)-tDCS during an intensive 3-week UL VRT and conventional therapy program on paretic UL function in chronic stroke. METHODS: The ReArm project is a quadruple-blinded, randomized, sham-controlled, bi-centre, two-arm parallel, and interventional study design. Fifty-eight chronic (> 3 months) stroke patients will be recruited from the Montpellier and Nimes University Hospitals. Patients will follow a standard 3-week in-patient rehabilitation program, which includes 13 days of VRT (Armeo Spring, 1 × 30 min session/day) and conventional therapy (3 × 30 min sessions/day). Twenty-nine patients will receive real stimulation (4x1 anodal HD-tDCS montage, 2 mA, 20 min) to the ipsilesional primary motor cortex during the VRT session and the other 29 patients will receive active sham stimulation (2 mA, 30 s). All outcome measures will be assessed at baseline, at the end of rehabilitation and again 3 months later. The primary outcome measure will be the wolf motor function test. Secondary outcomes will include measures of UL function (Box and Block Test), impairment (Fugl Meyer Upper Extremity), compensation (Proximal Arm Non-Use), ADL (Actimetry, Barthel Index). Other/exploratory outcomes will include pain, fatigue, effort and performance, kinematics, and motor cortical region activation during functional motor tasks. DISCUSSION: This will be the first trial to determine the impact of adding HD-tDCS during UL VRT and conventional therapy in chronic stroke patients. We hypothesize that improvements in UL function will be greater and longer-lasting with real stimulation than in those receiving sham. TRIAL REGISTRATION: The ReArm project was approved by The French Research Ethics Committee, (Comité de Protection des Personnes-CPP SUD-EST II, N°ID-RCB: 2019-A00506-51, http://www.cppsudest2.fr/ ). The ReArm project was registered on ClinicalTrials.gov ( NCT04291573 , 2nd March 2020.
引用
- Muller CO, Muthalib M, Mottet D, et al. Recovering arm function in chronic stroke patients using combined anodal HD-tDCS and virtual reality therapy (ReArm): a study protocol for a randomized controlled trial. Trials. 2021. PMID: 34702317. doi:10.1186/s13063-021-05689-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。